MAPT and major depressive disorder: Importantly, preclinical studies show that serotonergic agents have multiple mechanisms relevant to prevention and symptomatic treatment of both depression and cognitive deficits, in addition to blocking Aβ and Tau, neuroprotection and synaptic plasticity [73].